Hannah Hurley

I'll research Hannah Hurley's professional background before drafting.

Good detail on the Neurelis matters. Let me pull her firm bio and verify education/admissions plus the Lupin trial.

Let me check the Lupin matter's outcome and pull her full firm bio for any additional details.

Hannah Hurley — Patent Litigation Practice Summary

Focus areas. Hurley is an IP litigation associate at McDermott Will & Emery (McDermott Will & Schulte LLP), based in the firm's Menlo Park, California office. Her firm bio describes her practice simply as "intellectual property litigation," and her published commentary spans patent, trademark, copyright and trade-secret decisions, including Federal Circuit and PTAB rulings and the Unified Patent Court. Her actual tracked docket, however, is concentrated in Hatch-Waxman / ANDA pharmaceutical patent litigation. All five tracked appearances arise out of the Valtoco® (diazepam nasal spray) patent family asserted by Neurelis, Inc. — formulation and method-of-use patents covering intranasal benzodiazepine solutions — so her hands-on patent experience to date is pharma/life-sciences rather than Wi-Fi, software or mechanical arts. Her undergraduate degree in biology is consistent with that technical fit.

Side preference. She is predominantly plaintiff/brand-side. Four of five tracked appearances are for Neurelis as plaintiff in ANDA infringement suits; the single "defendant-side" entry is Padagis US LLC v. Neurelis, Inc., which is the PTAB proceeding (and related posture) in which Neurelis appears as patent owner and Hurley served as back-up counsel. That is defending a patent rather than defending an operating company accused of infringement, so her record does not show NPE/PAE-side prosecution of claims or a genuine mixed plaintiff/defendant infringement practice. The counts should be read as a brand-pharma patent owner practice, not as "both sides" in the conventional sense.

Notable matters and firm context. Her most prominent tracked matters are Neurelis, Inc. v. Lupin Inc. et al. (D. Del.), where she is identified as trial counsel in a multi-patent Valtoco ANDA action, and Neurelis, Inc. v. Amneal Pharmaceuticals LLC (D. Del.), where she was admitted pro hac vice for Neurelis. Both involve the '546, '414, '786, '664 and '400 patents and Paragraph IV certifications by generic filers; the parallel Neurelis v. Padagis action was set for a February 2026 trial date per Neurelis's PTAB briefing. McDermott is her only firm identified in the tracked data, and I found no prior-firm history in publicly available sources. I could not verify a trial verdict, judgment or settlement in any of these matters, so no outcome should be attributed to her on this record.

PTAB / IPR and credentials. She does appear in AIA post-grant proceedings: the Board granted her pro hac vice admission as back-up counsel for Patent Owner Neurelis in Padagis US LLC v. Neurelis, Inc., IPR2025-00464, -00465 and -00466 (challenging the '546, '414 and '786 patents), where Neurelis advanced Fintiv-based discretionary-denial arguments. Her PTAB role is back-up, not lead, counsel. She was admitted to the California bar on December 3, 2024 (Bar No. 357794); reviewed sources do not indicate registration to practice before the USPTO, consistent with her pro hac vice rather than registered-practitioner appearance at the Board. Education: JD with honors, Emory University School of Law (notes and comments editor, Emory Law Journal); BS in Biology, UCLA; judicial extern to Judge Amy Totenberg, N.D. Ga. She is an early-career attorney — the 2024 bar admission date means the "trial counsel" and other role labels in the tracked data reflect a junior attorney's staffing on a large McDermott trial team rather than first-chair experience.